Top 5 Stocks to Buy Now
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NYSEAMERICAN:PHGE

BiomX Q4 2025 Earnings Report

BiomX logo
$0.52 0.00 (0.00%)
As of 06/18/2026 04:10 PM Eastern
ProfileEarnings HistoryForecast

BiomX EPS Results

Actual EPS
$6.99
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BiomX Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BiomX Announcement Details

Quarter
Q4 2025
Date
2/19/2026
Time
After Market Closes
Conference Call Date
Thursday, February 19, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

BiomX's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

BiomX's Q4 2025 Annual reportAnnual report
(10-K)

BiomX Earnings Headlines

BiomX Inc. Posts Updated Presentation Highlighting Defense-Sector Transition and Growth Strategy
June 18 at 9:31 AM  |  quiverquant.comQ
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
June 18 at 9:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3314262/0/en/biomx-provides-update-on-defense-technology-portfolio-and-growth-strategy.html
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
June 21 at 1:00 AM  |  Weiss Ratings (Ad)
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311074/0/en/biomx-announces-nyse-american-acceptance-of-plan-to-regain-compliance.html
BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Update
June 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30834338
BiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events
June 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/biomx-zorronet-s-ai-security-experts-provide-in-depth-review-on-why-security-ai-must-move-beyond-detection-to-understanding-in-high-stakes-global-events-1036242349
See More BiomX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BiomX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BiomX and other key companies, straight to your email.

About BiomX

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways.

Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.

View BiomX Profile
Earnings Tools